WASHINGTON — Early feedback on the Food and Drug Administration’s proposal on naming conventions for biosimilars shows a mixed response. Late late week, the FDA published draft guidance recommending that reference biologic products and biosimilars have nonproprietary names that share a core drug substance name and an FDA-designated suffix unique for each product. For interchangeable
WASHINGTON — Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down. GPhA said Wednesday that Davis, previously executive vice president for advocacy and member relations at Pharmaceutical Research and Manufacturers of America (PhRMA), is slated to start in
WASHINGTON — The Generic Pharmaceutical Association (GPhA) and its recently formed Biosimilars Council have praised the enactment of new legislation in five states to allow automatic substitution for Food and Drug Administration-approved interchangeable biologic products. Bills in Colorado (SB 71), Georgia (SB 51), Tennessee (SB 984), Utah (HB 279) and Washington (SB 5935) reflect core
WASHINGTON — A coalition of 11 biopharmaceutical companies has formed the Biosimilars Forum, described as the first nonprofit organization for expanding patient access to biosimilars in the United States. The group said Tuesday that its founding members represent the majority of companies with the most significant U.S. biosimilars development portfolios, including Actavis, Amgen, Boehringer Ingelheim,
